Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (374)	11/20/1999 1:19:00 PM
From: WTDEC	Read Replies (2) \| Respond to of 666

V1, I had a chance to review the most recent research on CLTR from Rachel at WDR, Ginsberg at USB-PJ, Bob Toth at PruV as well as Ende. All comprehended the ASH abstracts. Ende can, IMO, be described as an outlier. The others range from strongly to at least mildly bullish on Bexxar/CLTR. The weight of evidence seems to tilt solidly, if not overwhelmingly, to Bexxar. You say "if" Bexxar gets approved before Zev. I read that as a statement of frustration rather than one based on new facts. Please let us know if this is a wrongheaded interpretation <G>. Best regards, Walter